Corcept Therapeutics Incorporated (CORT) is a Healthcare · Biotechnology company listed on NASDAQ. Price $110.29 (-3.98%), Market cap $6.26B, P/E ratio 166.57, 52-week low–high $32.15 ~ $90.32.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-ass
Financial statements, price targets, institutional (13F) holdings and related news for Corcept Therapeutics Incorporated are updated in real time on BlackAll Trade.
Corcept Therapeutics Incorporated trades at $110.29 (-3.98%). Real-time quotes and charts are available on BlackAll Trade.
Corcept Therapeutics Incorporated has a market cap of about $6.26B. Its P/E ratio is 166.57.
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders i